Brief: Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav
16/05/2025 12:32
May 16 (Reuters) - Neurogene Inc NGNE.O: NEUROGENE ANNOUNCES EVIDENCE-BASED MONITORING AND TREATMENT INTENDED TO REVERSE RARE HYPERINFLAMMATORY SYNDROME ASSOCIATED WITH HIGH-DOSE AAV Source text: ID:nBwcgjFs7a Further company coverage: NGNE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable